BioMarin Pharmaceutical Inc. (BMRN) Q3 2016 Earnings Results

BioMarin Pharmaceutical Beats on EPS, Stock Down 0.89%

BioMarin's earnings report shows a positive surprise on EPS, indicating better-than-expected performance in that area. However, the stock reacted negatively, declining by 0.89%. This could reflect investor concerns about the lack of revenue data and future guidance, which may lead to uncertainty about the company's growth trajectory.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.26	N/A	+32.99%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management conveyed a sense of cautious optimism regarding their product pipeline. They emphasized their commitment to long-term growth, even amidst current challenges.

Management highlighted ongoing progress in their pipeline.

They expressed confidence in future product launches.

The focus remains on long-term growth despite current challenges.

BioMarin Pharmaceutical Beats on EPS, Stock Down 0.89%

Key numbers

Management commentary

BioMarin Pharmaceutical Inc.

More earnings this week

BioMarin Pharmaceutical Beats on EPS, Stock Down 0.89%

Key numbers

Management commentary